Hims & Hers shares jumped over 50% in premarket trading after reports Novo Nordisk will sell its weight-loss drugs on Hims & Hers' telehealth platform, signaling a potential end to the companies' dispute. The development suggests a meaningful commercial partnership and revenue upside for Hims & Hers while removing a legal overhang that likely triggered the sharp stock move.
Hims & Hers shares jumped over 50% in premarket trading after reports Novo Nordisk will sell its weight-loss drugs on Hims & Hers' telehealth platform, signaling a potential end to the companies' dispute. The development suggests a meaningful commercial partnership and revenue upside for Hims & Hers while removing a legal overhang that likely triggered the sharp stock move.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
